Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dr Reddys launches...

    Dr Reddys launches antidepressant, muscle relaxant tablets in US

    Written by Ruby Khatun Khatun Published On 2017-09-07T11:19:01+05:30  |  Updated On 18 Aug 2021 3:01 PM IST

    New Delhi: Dr. Reddy's Laboratories on Wednesday said it has launched Bupropion Hydrochloride extended-release tablets used in treating a major depressive disorder in the American market.


    It has also launched Metaxalone tablets used to ease discomforts associated with acute, painful musculoskeletal conditions in the US market.

    The company has launched Bupropion Hydrochloride extended-release tablets USP (XL) in the strengths of 150 mg and 300 mg, Dr. Reddy's said in a filing to BSE.

    The tablets are generic versions of GlaxoSmithKline LLC's Wellbutrin XL tablets, it added.

    As per IMS Health, the Wellbutrin XL brand and generic had US sales of around USD 754 million MAT for the twelve months ended July 2017, Dr. Reddy's said.

    The company has also launched Metaxalone tablets USP 800 mg in the American market, it added.

    The tablets are generic versions of King Pharmaceuticals Research and Development Inc's Skelaxin tablets.

    "The Skelaxin brand and generic had US sales of around USD 139 million MAT for the most recent twelve months ended July 2017, according to IMS Health," Dr. Reddy's said.
    American marketantidepressantBupropion HydrochlorideBupropion Hydrochloride extended release tabletsDr Reddy'sDr Reddy's LaboratoriesgenericGlaxoSmithKlineKing Pharmaceuticalslaunchesmajor depressive disordersMetaxalone tabletsmuscle relaxantmusculoskeletal conditionsSkelaxinTabletsUSWellbutrin XL
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok